AGI-6780|cas 1432660-47-3|DC Chemicals

Cas No.:	1432660-47-3
Chemical Name:	1-[5-(Cyclopropylsulfamoyl)-2-Thiophen-3-Yl-Phenyl]-3-[3-(Trifluoromethyl)phenyl]urea
Synonyms:	AGI-6780;1-[5-(cyclopropylsulfamoyl)-2-thiophen-3-ylphenyl]-3-[3-(trifluoromethyl)phenyl]urea;N-Cyclopropyl-4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzenesulfonamide;AGI 6780;FD5013;QCR-283;N-Cyclopropyl-4-(3-thienyl)-3-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-benzenesulfonamide;AGI6780;AK162157;1-[5-(Cyclopropylsulfamoyl)-2-Thiophen-3-Yl-Phenyl]-3-[3-(Trifluoromethyl)phenyl]urea;MLS006011046;C21H18F3N3O3S2;AOB2268;HMS3744K17;HMS3653I21;BDBM339679;BCP07383;US10202339, Compound 124;s7241;2198AH;SB19578;NCGC0034
SMILES:	S(C1C([H])=C([H])C(C2=C([H])SC([H])=C2[H])=C(C=1[H])N([H])C(N([H])C1=C([H])C([H])=C([H])C(C(F)(F)F)=C1[H])=O)(N([H])C1([H])C([H])([H])C1([H])[H])(=O)=O
Formula:	C₂₁H₁₈F₃N₃O₃S₂
M.Wt:	481.5111
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2WT with IC50 of 190±8.1 nM.

In Vitro:

AGI-6780 is tested in both human glioblastoma U87 and TF-1 cells expressing IDH2R140Q, as well as against IDH1R132H for 48 h incubation, with IC50 of 11±2.6 nM, 18±0.51 nM, and >1 mM, respectivly.Treatment of TF-1R140Q cells with AGI-6780, at concentrations that lower 2HG to near-normal physiologic levels, restore expression of both HBG and KLF1 genes and the color change associated with differentiation. AGI-6780 can reverse the IDH2R140Q-induced differentiation block in TF-1 cells. Pretreatment with AGI-6780 (0.2 μM and 1 μM) markedly decreased the intracellular concentration of (R)-2-hydroxyglutarate in the TF1R140Q cells and restored their ability to undergo EPO-induced differentiation[1].

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC7982	Mutant IDH1-IN-1	Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent).
DC10830	IDH-889	IDH889 is a potent and selective inhibitors of IDH1. IDH899 shows IDH (R132H) IC50 = 20 nM; Cell 2-HG IC50 = 14 nM.
DC10538	IDH-305	IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity.
DC7174	AGI-6780	AGI-6780 is the first highly potent and selective small molecule inhibitor of isocitrate dehydrogenases, which binds in an allosteric manner at the dimer interface of mutant IDH2-R140Q (IC50=23 nM).
DC5050	AGI-5198	AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
DC10439	Vorasidenib (AG881)	AG-881 is a potent and selective orally available inhibitor of mutated forms of both isocitrate dehydrogenase type 1 (IDH1) in the cytoplasm and type 2 (IDH2).
DC8374	AG-221(Enasidenib)	AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.
DC8051	AG-120 (Ivosidenib)	AG-120 is a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein.